Community Partnership for Telehealth Solutions to Convey Information and Enhance Care
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- University of Arizona
- Study ID
- NCT06542835
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 45 Years - 64 Years
- Healthy Volunteers
- Not accepted
Interventions
- Video text message — BEHAVIORALVideo text messages tailored to the Latinx population to educate and motivate patients to complete CRC screening.
- In-clinic CRC screening promotion — BEHAVIORALStool-test orders, colonoscopy referrals.
- Mailed FIT — BEHAVIORALMailed FIT kits.
- Social needs navigation — BEHAVIORALPatient navigation to address social needs.
- Reminders — BEHAVIORALCentralized text and/or telephone reminders for ordered tests.
Study Details
Non-randomized, two-arm stepped-wedge trial of a multi-level colorectal cancer screening intervention.
Key Dates
- Start date
- Jul 31, 2024
- Status verified
- Mar 2026
- Primary completion
- Oct 31, 2026
- Completion
- Jan 31, 2027
Study Design
- Enrollment
- 6,000 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- SCREENING
Arms
- Experimental: Video text message, mailed FIT, and social needs navigationTailored video text message, mailed FIT, and navigation to address patients' social needs.
- Active Comparator: Usual careColorectal cancer (CRC) screening offers during in-person clinic visits.
Primary Outcome Measure
CRC Screening Completion at the Individual Level [ Time Frame: 6 months ]
Central Contacts
- Gloria Coronado, PhD5039147100
- Katherine Mendoza, MPH8477672847
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| AltaMed Health Services Corporation | Los Angeles | California | 90040 |
Find similar trials in Los Angeles, CA
By condition
By specialty
By research site
Related Studies
- ColoCare Study - Colorectal Cancer CohortRecruiting · University of Utah · Los Angeles, California
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Merus B.V. · La Jolla, California
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsPHASE1/PHASE2 · Recruiting · IDEAYA Biosciences · Los Angeles, California
- Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid MalignanciesPHASE1 · Recruiting · BioEclipse Therapeutics · Scottsdale, Arizona